Carisoprodol 350 mg Tablet, 100-count
by Actavis Pharma, Inc. · 100 TABLET in 1 BOTTLE (0591-5513-01)
NDC 00591-5513-01
🏷️ FDA NDC (as labeled)
0591-5513-01
billing pads the labeler segment with a zero
This package
Discontinued
CIV
⚠ Discontinued by firm
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →
⚠️
Excluded from the active FDA NDC Directory.
The labeler reported this product as discontinued, so it is excluded from the active NDC Directory. The listing was last certified through Apr 2024. A label may still appear on DailyMed, but the NDC is no longer in the current FDA NDC Directory.
Search the FDA NDC Directory ↗
🆔 Identity & classification
FDA NDC (as labeled)
0591-5513-01
Product NDC
0591-5513
11-digit billing NDC
00591551301
NCPDP billing unit
EA — each (per item)
SPL Set ID
4a15bd91-cbb3-46a8-ab0a-1e153c72d97a
DEA schedule
CIV
Marketing category
DRUG FOR FURTHER PROCESSING
Marketing status
Discontinued
FDA listing status
Discontinued by firm (certified through Apr 2024)
Marketing start
1987-11-01
Dosage form
TABLET
Substance
CARISOPRODOL
GPI-14
75100020000305
GPI class
Carisoprodol
GCN Seq No
004663
GCN
17912
HICL code
001944
Ingredient (HICL)
Carisoprodol
HIC1 code
H
Therapeutic class — broad (HIC1)
Nervous System (Except Autonomic)
HIC2 code
H6
Therapeutic class — intermediate (HIC2)
Drugs Acting Principally On The Midbrain
HIC3 code
H6H
Therapeutic class — specific (HIC3)
Skeletal Muscle Relaxants
AHFS code
12:20.04.00
AHFS class
Centrally Acting Skeletal Muscle Relaxnt
FDB label name
CARISOPRODOL 350 MG TABLET
FDB brand name
Carisoprodol
Legend status
F — Federal legend — prescription drug or device
Why two NDCs?
The FDA registers this code as 0591-5513-01 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00591-5513-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.
🏭 Manufacturer & labeler
LabelerActavis Pharma, Inc.
Labeler code00591
First marketedNov 1987
DEA scheduleCIV
Product typeDrug For Further Processing
Portfolio324 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.
🩺 Clinical
Label name CARISOPRODOL 350 MG TABLET Ingredient Carisoprodol
📖 What it is MedlinePlus · NLM
Carisoprodol is used with rest, physical therapy, and other measures to relax muscles and relieve pain and discomfort caused by strains, sprains, and other muscle injuries. Carisoprodol is in a class of medications called skeletal muscle relaxants. It works by acting in the brain and nervous system to allow the muscles to relax.
Read the full MedlinePlus article ↗📗 Our plain-language guide HelloPharmacist
- Carisoprodol — you may know it by the brand name Soma — is a short-term muscle relaxant for adults dealing with acute muscle pain and discomfort, like a back injury or muscle strai...
- Yes, drowsiness is the most common side effect — it happened in up to 17% of people in clinical trials. You should not drive or operate heavy machinery until you know how carisopro...
- Will it make me really drowsy? Can I drive?
- There is a real risk. Carisoprodol can be habit-forming, and cases of abuse and dependence have been reported — especially with prolonged use or in people with a history of substan...
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Carisoprodol — tap one for details:
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.
💬 Questions about Carisoprodol?
Ask a pharmacist →
Ask a licensed pharmacist directly — free, answered by our team.
🧪 Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured
IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per ea | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $0.071 | $7.12 / 100 tablets |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
NADAC price history (per ea) — tap or hover for the price & month
▲ Up 20% over the last 15 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.
🔁 Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Carisoprodol 350 mg 42543-0700-01 | Vensun | 100 tablets | $0.051 | AA | FDA listed | save 28% |
| carisoprodol 350 mg 16571-0781-01 | Rising | 100 tablets | $0.067 | AB | Availability likely | save 6% |
| Carisoprodol 350 mg 50228-0109-01 | ScieGen | 100 tablets | $0.067 | AA | Availability likely | save 6% |
| Carisoprodol 350 mg 50742-0656-01 | Ingenus | 100 tablets | $0.067 | AA | Availability likely | save 6% |
| Carisoprodol 350 mg 62135-0241-12 | Chartwell | 120 tablets | $0.067 | AA | Availability likely | save 6% |
| Carisoprodol Tablets, USP, 350 mg 63561-0127-01 | Granulation | 100 tablets | $0.067 | AA | Availability likely | save 6% |
| Carisoprodol 350 mg 69367-0420-01 | Westminster | 100 tablets | $0.067 | AB | Availability likely | save 6% |
| Carisoprodol 350 mg 69584-0111-10 | Oxford | 100 tablets | $0.067 | AA | Availability likely | save 6% |
| carisoprodol 350 mg 65862-0158-01 | Aurobindo | 100 tablets | $0.071 | — | FDA listed | — |
| Carisoprodol 350 mgthis 00591-5513-01 | Actavis | 100 tablets | $0.071 | — | Discontinued | — |
| Soma 350 mg 00037-2001-01 | Viatris | 100 tablets | $11.386 | AB | Availability likely | +15889% |
| Carisoprodol 350 mg 45865-0233-30 | Medsource | 30 tablets | — | AA | FDA listed | — |
| Carisoprodol 350 mg 50090-5953-05 | A-S | 90 tablets | — | AA | FDA listed | — |
| Carisoprodol 350 mg 50090-5955-00 | A-S | 30 tablets | — | AA | FDA listed | — |
| Carisoprodol 350 mg 52536-0688-10 | Wilshire | 100 tablets | — | AB | FDA listed | — |
| Carisoprodol 350 mg 60760-0397-90 | St. | 90 tablets | — | AA | FDA listed | — |
| Carisoprodol 350 mg 61919-0878-60 | Direct_Rx | 60 tablets | — | AA | FDA listed | — |
| Carisoprodol 350 mg 63629-2416-01 | Bryant | 100 tablets | — | AA | FDA listed | — |
| Carisoprodol 350 mg 63629-8477-01 | Bryant | 1000 tablets | — | AA | FDA listed | — |
| Carisoprodol 350 mg 63629-8478-01 | Bryant | 500 tablets | — | AA | FDA listed | — |
| Carisoprodol 350 mg 63629-8479-01 | Bryant | 100 tablets | — | AA | FDA listed | — |
| carisoprodol 350 mg 68071-3421-06 | NuCare | 60 tablets | — | AB | FDA listed | — |
| Carisoprodol 350 mg 68071-5075-03 | NuCare | 30 tablets | — | AA | FDA listed | — |
| Carisoprodol 350 mg 70518-2800-00 | REMEDYREPACK | 60 tablets | — | AA | FDA listed | — |
| carisoprodol 350 mg 70518-3792-00 | REMEDYREPACK | 90 tablets | — | AB | FDA listed | — |
| Carisoprodol 350 mg 71205-0241-20 | Proficient | 20 tablets | — | AA | FDA listed | — |
| Carisoprodol 350 mg 71205-0339-30 | Proficient | 30 tablets | — | AA | FDA listed | — |
| Carisoprodol 350 mg 71205-0704-30 | Proficient | 30 tablets | — | AA | FDA listed | — |
| Carisoprodol 350 mg 71335-1203-00 | Bryant | 56 tablets | — | AA | FDA listed | — |
| Carisoprodol Tablets, USP, 350 mg 71335-3018-01 | Bryant | 1000 tablets | — | AA | FDA listed | — |
| carisoprodol 350 mg 71335-9613-00 | Bryant | 56 tablets | — | AB | FDA listed | — |
| Carisoprodol 350 mg 71335-9621-00 | Bryant | 56 tablets | — | AA | FDA listed | — |
| Carisoprodol 350 mg 71610-0617-30 | Aphena | 30 tablets | — | AA | FDA listed | — |
| Carisoprodol 350 mg 71610-0761-30 | Aphena | 30 tablets | — | AA | FDA listed | — |
| Carisoprodol 350 mg 72162-1524-00 | Bryant | 1000 tablets | — | AA | FDA listed | — |
| Carisoprodol 350 mg 72162-1928-01 | Bryant | 100 tablets | — | AA | FDA listed | — |
| Carisoprodol Tablets, USP, 350 mg 72162-2525-00 | Bryant | 1000 tablets | — | AA | FDA listed | — |
| Carisoprodol 350 mg 72189-0310-30 | Directrx | 30 tablets | — | AA | FDA listed | — |
| Carisoprodol 350 mg 72189-0386-30 | Direct_Rx | 30 tablets | — | AB | FDA listed | — |
| Carisoprodol 350 mg 72789-0182-01 | PD-Rx | 100 tablets | — | AA | FDA listed | — |
| Carisoprodol 350 mg 72789-0190-14 | PD-Rx | 14 tablets | — | AA | FDA listed | — |
| Carisoprodol Tablets, USP, 350 mg 72789-0477-01 | PD-Rx | 100 tablets | — | AA | FDA listed | — |
| Carisoprodol 350 mg 76420-0646-01 | Asclemed | 100 tablets | — | AA | FDA listed | — |
| carisoprodol 350 mg 76420-0853-00 | Asclemed | 1000 tablets | — | AB | FDA listed | — |
| Carisoprodol 350 mg 80425-0291-01 | Advanced | 30 tablets | — | AA | FDA listed | — |
| Carisoprodol 350 mg 82868-0062-30 | Northwind | 30 tablets | — | AA | FDA listed | — |
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.
⏳ Availability & generic status
🏛️
1987
On the market since
Nov 1987
📍
2026
Currently FDA-listed
39 years listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available
FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.
Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.
📊 Medicare Part D spend CMS · PART D · 2026 (Q1)
Medicare Part D (outpatient prescription) spending for Carisoprodol (matched by generic name) — the program that covers self-administered drugs. 7 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Carisoprodol. CMS lists 2 products for this generic; we show the highest-spend one. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$856.8K
Claims incl. refills
64.2K
Beneficiaries
36.6K
Spend / beneficiary
$23.39
Spend / claim
$13.35
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
🔬 Reported adverse events (FAERS)
Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Carisoprodol — the ingredient across all brands.
Top reported reactions
Age at onset
Reporter sex
Male · 29%
Female · 71%
Unknown · 0%
Serious outcomes
Reports over time (by year) — tap or hover for the count & year
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
📦 Packaging — all sizes for this product
| Package NDC | Description | Per unit | Per pack | Marketing start | Status |
|---|---|---|---|---|---|
| 00591-5513-01 You're viewing this | 100 TABLET in 1 BOTTLE (0591-5513-01) | $0.0712 / ea | $7.12 | 1987-11-01 | Discontinued by firm |
| 00591-5513-05 | 500 TABLET in 1 BOTTLE (0591-5513-05) | $0.0712 / ea | $35.61 | 1987-11-01 | Discontinued by firm |
| 00591-5513-10 | 1000 TABLET in 1 BOTTLE (0591-5513-10) | $0.0712 / ea | $71.21 | 1987-11-01 | Discontinued by firm |
| 00591-5513-00 | 22200 TABLET in 1 BAG (0591-5513-00) | — | — | — | Active |
You're viewing the smallest of 4 pack sizes for this product.
This pack has the lowest per-ea cost of the 3 priced pack sizes ($0.0712 NADAC).
Pack size FAQ
What quantity is in NDC 00591-5513-01?
NDC 00591-5513-01 is a 100-count package — 100 tablet in 1 bottle.
What is the difference between NDC 00591-5513-01 and NDC 00591-5513-05?
Both are Carisoprodol 350 mg Tablet — the drug itself is identical. NDC 00591-5513-01 is the 100-count package, while NDC 00591-5513-05 is the 500 tablets package.
What NDC number is used to bill for this package of Carisoprodol 350 mg Tablet?
Bill NDC 00591-5513-01 — the 11-digit billing format is 00591551301. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
🧭 About this NDC listing & data coverage
Listed for further processing / repackaging
No longer marketed (per FDA listing data)
What "drug for further processing" means
FDA lists this package under the "drug for further processing" marketing category: Actavis Pharma, Inc. supplies it to other companies for further processing or repackaging (blister cards that are later repackaged or co-packaged are a common example). The units themselves are a finished dosage form — which is why pricing or Medicaid data can still appear — but this exact package code may not be the presentation a retail pharmacy dispenses.
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | — Not published for this NDC No photo available yet for this listing. |
| Inactive ingredients (structured) | — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available. |
| NADAC pharmacy acquisition price (CMS) | ✓ Available |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.
Questions about this listing
Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Drug For Further Processing". Products approved under an application carry an NDA, ANDA, or BLA number.
What does the discontinued status mean for this NDC?
The labeler reported a marketing end date (or the listing was delisted), so this specific package is no longer actively marketed. Remaining stock may still be dispensed for a time, and the NDC stays valid for historical records and claims — but data feeds (pricing, labeling) typically stop updating for it. Other package sizes or other manufacturers' versions of the same medication may still be marketed — see the equivalents section where available.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The FDA registers it as 0591-5513-01, which is what is printed on the packaging and shown on DailyMed. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero: 00591-5513-01, written without dashes as 00591551301. The Identity section at the top of this page lists every form of this code.
What do the three segments of this NDC mean?
In 00591-5513-01, the first segment (00591) is the labeler code FDA assigned to Actavis Pharma, Inc.; the middle segment (5513) identifies this specific product — its ingredient, strength, and dosage form; and the last segment (01) identifies this exact package size and type. Together they name one specific package of one specific product.
Does this product come in other package sizes?
Yes — the FDA directory lists 3 other package presentations of this same product, including 500 tablets (00591-5513-05), 1000 tablets (00591-5513-10), 22200 tablets (00591-5513-00). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Actavis Pharma, Inc. is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
📄 Full FDA label FDA SPL
The complete FDA label for this product, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label ▾
No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.
No label section mentions that — try another word, or open the full label on DailyMed below.
Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA.
Prefer the government’s original formatting? View this label on DailyMed ↗
For educational and professional reference only — not medical advice. Pricing reflects published
NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.